

# Sebastian Schneeweiss

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8414270/publications.pdf>

Version: 2024-02-01

339  
papers

27,394  
citations

6613

79  
h-index

6996

154  
g-index

347  
all docs

347  
docs citations

347  
times ranked

25059  
citing authors

#	ARTICLE	IF	CITATIONS
1	Emulation of a randomized controlled trial in ulcerative colitis with <scp>US</scp> and French claims data: Infliximab with thiopurines compared to infliximab monotherapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 167-175.	1.9	5
2	Evolving channeling in prescribing <scp>SGLT</scp>-inhibitors as first-line treatment for type 2 diabetes. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 566-576.	1.9	2
3	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2022, 175, W4-W5.	3.9	0
4	Transparency of high-dimensional propensity score analyses: Guidance for diagnostics and reporting. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 411-423.	1.9	7
5	A Framework for Visualizing Study Designs and Data Observability in Electronic Health Record Data. <i>Clinical Epidemiology</i> , 2022, Volume 14, 601-608.	3.0	5
6	Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin. <i>Annals of Internal Medicine</i> , 2022, 175, 927-937.	3.9	20
7	Risk of connective tissue disease, morphea and systemic vasculitis in patients with hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 195-202.	2.4	5
8	Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 300-311.	1.2	20
9	Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees. <i>European Journal of Haematology</i> , 2021, 106, 273-280.	2.2	5
10	Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies. <i>Circulation</i> , 2021, 143, 1002-1013.	1.6	174
11	Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. <i>Diabetes Care</i> , 2021, 44, 826-835.	8.6	66
12	Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA. <i>Journal of General Internal Medicine</i> , 2021, 36, 2601-2607.	2.6	9
13	Real-world evidence of bariatric surgery and cardiovascular benefits using electronic health records data: A lesson in bias. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1453-1462.	4.4	12
14	Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 816-828.	4.7	29
15	Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp>. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1542-1551.	4.4	23
16	Greedy caliper propensity score matching can yield variable estimates of the treatment-outcome association-A simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 934-951.	1.9	9
17	Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments. <i>Endocrine Reviews</i> , 2021, 42, 658-690.	20.1	50
18	A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00237.	2.4	6

#	ARTICLE	IF	CITATIONS
19	Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. <i>JAMA Dermatology</i> , 2021, 157, 805.	4.1	21
20	Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. <i>Diabetes Care</i> , 2021, 44, 1774-1782.	8.6	24
21	Reply to the Letter by Arterburn D. et al. ("Bias in EHR-based studies: Seeing the Forest for the Trees"). <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1694-1695.	4.4	0
22	The modifying effects of adiposity on the cardiovascular safety of sulphonylureas. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2502-2512.	4.4	0
23	Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2320-2328.	4.4	12
24	Response by Franklin and Schneeweiss to Letters Regarding Article, "Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative". <i>Circulation</i> , 2021, 144, e162-e163.	1.6	3
25	Validation of obesity-related diagnosis codes in claims data. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2623-2631.	4.4	20
26	Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results. <i>Health Technology Assessment</i> , 2021, 25, 1-70.	2.8	0
27	Single-arm oncology trials and the nature of external controls arms. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1053-1066.	1.4	6
28	Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2021, 174, 1214-1223.	3.9	48
29	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 1528-1541.	3.9	52
30	Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 221-228.	3.0	6
31	Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 817-826.	4.7	76
32	Choosing Among Common Data Models for Real-World Data Analyses Fit for Making Decisions About the Effectiveness of Medical Products. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 827-833.	4.7	29
33	Kim et al. Respond to "Estimation With Claims-Based Frailty Indexes". <i>American Journal of Epidemiology</i> , 2020, 189, 373-374.	3.4	0
34	When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety. <i>Arthritis and Rheumatology</i> , 2020, 72, 4-6.	5.6	7
35	Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes. <i>JAMA Network Open</i> , 2020, 3, e1918962.	5.9	152
36	Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1405-1419.	4.7	12

#	ARTICLE	IF	CITATIONS
37	Using nationally representative survey data for external adjustment of unmeasured confounders: An example using the NHANES data. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1151-1158.	1.9	4
38	Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice. <i>Annals of Internal Medicine</i> , 2020, 172, 463.	3.9	72
39	Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. <i>Value in Health</i> , 2020, 23, 1128-1136.	0.3	68
40	Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries. <i>Annals of Hematology</i> , 2020, 99, 2497-2505.	1.8	12
41	Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity. <i>Drugs</i> , 2020, 80, 1961-1972.	10.9	24
42	Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 350-357.	4.7	41
43	Serious infection risk in children with psoriasis on systemic treatment: A propensity score-matched population-based study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1337-1345.	1.2	9
44	&lt;p&gt;Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model&lt;p&gt;. <i>Clinical Epidemiology</i> , 2020, Volume 12, 607-616.	3.0	15
45	&lt;p&gt;External Validation of an Algorithm to Identify Patients with High Data-Completeness in Electronic Health Records for Comparative Effectiveness Research&lt;p&gt;. <i>Clinical Epidemiology</i> , 2020, Volume 12, 133-141.	3.0	18
46	Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013–2018. <i>Diabetes Care</i> , 2020, 43, 921-924.	8.6	65
47	Application of a Graphical Depiction of Longitudinal Study Designs to Managed Care Pharmacy Research. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2020, 26, 268-274.	0.9	4
48	Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 735-737.	4.7	27
49	Improving measurement of binary covariates in claims data: A simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1093-1100.	1.9	1
50	Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2020, 156, 342.	4.1	16
51	Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 874-884.	4.7	2
52	Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases. <i>Clinical Epidemiology</i> , 2019, Volume 11, 1-15.	3.0	78
53	Using Real-World Data to Extrapolate Evidence From Randomized Controlled Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1156-1163.	4.7	22
54	Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. <i>Drug Safety</i> , 2019, 42, 1355-1363.	3.2	1

#	ARTICLE	IF	CITATIONS
55	Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. Drug Safety, 2019, 42, 1287-1295.	3.2	13
56	Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride. Diabetes Care, 2019, 42, 2204-2210.	8.6	81
57	Discussion of Schuemie et al: "A plea to stop using the case-control design in retrospective database studies". Statistics in Medicine, 2019, 38, 4209-4212.	1.6	15
58	Desmopressin and the risk of hyponatremia: A population-based cohort study. PLoS Medicine, 2019, 16, e1002930.	8.4	16
59	A Case-Crossover-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data. Clinical Pharmacology and Therapeutics, 2019, 106, 238-244.	4.7	17
60	Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. Clinical Pharmacology and Therapeutics, 2019, 105, 1513-1521.	4.7	10
61	Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Annals of the Rheumatic Diseases, 2019, 78, 456-464.	0.9	139
62	Theory meets practice: a commentary on VanderWeele's "principles of confounder selection". European Journal of Epidemiology, 2019, 34, 221-222.	5.7	3
63	Real-World Evidence of Treatment Effects: The Useful and the Misleading. Clinical Pharmacology and Therapeutics, 2019, 106, 43-44.	4.7	26
64	Sequential Monitoring of the Comparative Effectiveness and Safety of Dabigatran in Routine Care. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005173.	2.2	8
65	Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 1442-1452.	0.9	12
66	Comparative risk of genital infections associated with sodium-glucose cotransporter-2 inhibitors. Diabetes, Obesity and Metabolism, 2019, 21, 434-438.	4.4	82
67	Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making. Clinical Pharmacology and Therapeutics, 2019, 105, 867-877.	4.7	112
68	Claims Data Studies of Direct Oral Anticoagulants Can Achieve Balance in Important Clinical Parameters Only Observable in Electronic Health Records. Clinical Pharmacology and Therapeutics, 2019, 105, 979-993.	4.7	11
69	Scalable collaborative targeted learning for high-dimensional data. Statistical Methods in Medical Research, 2019, 28, 532-554.	1.5	27
70	Collaborative-controlled LASSO for constructing propensity score-based estimators in high-dimensional data. Statistical Methods in Medical Research, 2019, 28, 1044-1063.	1.5	29
71	Clinical Outcomes Following Bone Marrow Transplant in Patients with Sickle Cell Disease: A Cohort Study of US Medicaid Enrollees. Blood, 2019, 134, 2166-2166.	1.4	0
72	Sequential surveillance for drug safety in a regulatory environment. Pharmacoepidemiology and Drug Safety, 2018, 27, 707-712.	1.9	7

#	ARTICLE	IF	CITATIONS
73	No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 399-405.	3.4	37
74	Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 383-390.	1.9	2
75	Simulation for Predicting Effectiveness and Safety of New Cardiovascular Drugs in Routine Care Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1008-1015.	4.7	3
76	Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 57-66.	1.4	2
77	Reuse of data sources to evaluate drug safety signals: When is it appropriate?. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 567-569.	1.9	11
78	Hypothesis-free screening of large administrative databases for unsuspected drug-outcome associations. <i>European Journal of Epidemiology</i> , 2018, 33, 545-555.	5.7	27
79	Real-world effects of medications for chronic obstructive pulmonary disease: protocol for a UK population-based non-interventional cohort study with validation against randomised trial results. <i>BMJ Open</i> , 2018, 8, e019475.	1.9	6
80	Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses. <i>American Journal of Epidemiology</i> , 2018, 187, 1799-1807.	3.4	56
81	Identifying Patients With High Data Completeness to Improve Validity of Comparative Effectiveness Research in Electronic Health Records Data. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 899-905.	4.7	40
82	Impact of drug reimbursement policies on prescribing: A case study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 95-104.	1.9	4
83	Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 974-984.	4.4	63
84	Use of Health Care Databases to Support Supplemental Indications of Approved Medications. <i>JAMA Internal Medicine</i> , 2018, 178, 55.	5.1	95
85	Development and Preliminary Validation of a Medicare Claims-Based Model to Predict Left Ventricular Ejection Fraction Class in Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004700.	2.2	36
86	Using Previous Medication Adherence to Predict Future Adherence. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 1146-1155.	0.9	29
87	Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1361-1370.	1.9	9
88	Virtual non-enhanced dual-energy CT reconstruction may replace true non-enhanced CT scans in the setting of suspected active hemorrhage. <i>European Journal of Radiology</i> , 2018, 109, 218-222.	2.6	14
89	Removal of ineligible outcome cases reduces confounding. <i>Clinical Epidemiology</i> , 2018, Volume 10, 575-579.	3.0	1
90	Defining Exposure in Observational Studies Comparing Outcomes of Treatment Discontinuation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004684.	2.2	6

#	ARTICLE	IF	CITATIONS
91	Real-World Data Analytics Fit for Regulatory Decision-Making. American Journal of Law and Medicine, 2018, 44, 197-217.	0.2	18
92	Automated data-adaptive analytics for electronic healthcare data to study causal treatment effects. Clinical Epidemiology, 2018, Volume 10, 771-788.	3.0	52
93	Association of Medicare's Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis. American Journal of Kidney Diseases, 2018, 72, 178-187.	1.9	15
94	Using Design Thinking to Differentiate Useful From Misleading Evidence in Observational Research. JAMA - Journal of the American Medical Association, 2017, 317, 705.	7.4	58
95	Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. Arthritis and Rheumatology, 2017, 69, 1154-1164.	5.6	160
96	Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis. Drug Safety, 2017, 40, 923-932.	3.2	11
97	Clinical Outcomes of Concomitant Use of Warfarin and Selective Serotonin Reuptake Inhibitors. Journal of Clinical Psychopharmacology, 2017, 37, 200-209.	1.4	16
98	Conducting Privacy-Preserving Multivariable Propensity Score Analysis When Patient Covariate Information Is Stored in Separate Locations. American Journal of Epidemiology, 2017, 185, 501-510.	3.4	3
99	Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. New England Journal of Medicine, 2017, 376, 2300-2302.	27.0	256
100	Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiology and Drug Safety, 2017, 26, 712-721.	1.9	27
101	From Trial to Target Populations – Calibrating Real-World Data. New England Journal of Medicine, 2017, 376, 1203-1205.	27.0	35
102	Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin. Drug Safety, 2017, 40, 169-181.	3.2	15
103	Variation in adherence to medications across the healthcare system in two comparative effectiveness research cohorts. Journal of Comparative Effectiveness Research, 2017, 6, 613-625.	1.4	2
104	Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. Value in Health, 2017, 20, 1003-1008.	0.3	243
105	A review of the performance of different methods for propensity score matched subgroup analyses and a summary of their application in peer-reviewed research studies. Pharmacoepidemiology and Drug Safety, 2017, 26, 1507-1512.	1.9	15
106	Synergies From Integrating Randomized Controlled Trials and Real-World Data Analyses. Clinical Pharmacology and Therapeutics, 2017, 102, 914-916.	4.7	7
107	When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?. Clinical Pharmacology and Therapeutics, 2017, 102, 924-933.	4.7	201
108	Improved CT-detection of acute bowel ischemia using frequency selective non-linear image blending. Acta Radiologica Open, 2017, 6, 205846011771822.	0.6	7



#	ARTICLE	IF	CITATIONS
109	Posing Causal Questions When Analyzing Observational Data—Reply. JAMA - Journal of the American Medical Association, 2017, 318, 201.	7.4	0
110	Assessment of Confounders in Comparative Effectiveness Studies From Secondary Databases. American Journal of Epidemiology, 2017, 185, 474-478.	3.4	6
111	Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors. American Journal of Cardiology, 2017, 119, 651-657.	1.6	21
112	Comparing the performance of propensity score methods in healthcare database studies with rare outcomes. Statistics in Medicine, 2017, 36, 1946-1963.	1.6	66
113	Developing alerting thresholds for prospective drug safety monitoring. Pharmacoepidemiology and Drug Safety, 2016, 25, 755-762.	1.9	0
114	Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications. Journal of Clinical Epidemiology, 2016, 76, 200-208.	5.0	21
115	“Threshold Crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials?. Clinical Pharmacology and Therapeutics, 2016, 100, 699-712.	4.7	61
116	Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision-Making. Clinical Pharmacology and Therapeutics, 2016, 100, 633-646.	4.7	44
117	Initiation patterns of statin therapy among adult patients undergoing intermediate to high-risk non-cardiac surgery. Pharmacoepidemiology and Drug Safety, 2016, 25, 64-72.	1.9	4
118	Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug-Adverse Event Association. Clinical Pharmacology and Therapeutics, 2016, 100, 558-564.	4.7	33
119	Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 2938-2944.	3.0	15
120	Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study. Arthritis and Rheumatology, 2016, 68, 2106-2113.	5.6	19
121	Improving therapeutic effectiveness and safety through big healthcare data. Clinical Pharmacology and Therapeutics, 2016, 99, 262-265.	4.7	27
122	Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs. Clinical Pharmacology and Therapeutics, 2016, 100, 147-159.	4.7	55
123	DECISION-MAKING ALIGNED WITH RAPID-CYCLE EVALUATION IN HEALTH CARE. International Journal of Technology Assessment in Health Care, 2015, 31, 214-222.	0.5	17
124	From adaptive licensing to adaptive pathways: Delivering a flexible life-span approach to bring new drugs to patients. Clinical Pharmacology and Therapeutics, 2015, 97, 234-246.	4.7	160
125	Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thrombosis and Haemostasis, 2015, 114, 1277-1289.	3.4	110
126	High-dimensional propensity score algorithm in comparative effectiveness research with time-varying interventions. Statistics in Medicine, 2015, 34, 753-781.	1.6	36



#	ARTICLE	IF	CITATIONS
127	A Unified Framework for Classification of Methods for Benefit-Risk Assessment. Value in Health, 2015, 18, 250-259.	0.3	16
128	Prospective Benefit-Risk Monitoring of New Drugs for Rapid Assessment of Net Favorability in Electronic Health Care Data. Value in Health, 2015, 18, 1063-1069.	0.3	3
129	Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study. Value in Health, 2015, 18, 1057-1062.	0.3	3
130	Regularized Regression Versus the High-Dimensional Propensity Score for Confounding Adjustment in Secondary Database Analyses. American Journal of Epidemiology, 2015, 182, 651-659.	3.4	50
131	Assessing the relative efficacy of new drugs: an emerging opportunity. Nature Reviews Drug Discovery, 2015, 14, 443-444.	46.4	16
132	Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications. Drug Safety, 2015, 38, 565-575.	3.2	31
133	Incorporating Linked Healthcare Claims to Improve Confounding Control in a Study of In-Hospital Medication Use. Drug Safety, 2015, 38, 589-600.	3.2	5
134	Addressing Limitations in Observational Studies of the Association Between Glucose-Lowering Medications and All-Cause Mortality: A Review. Drug Safety, 2015, 38, 295-310.	3.2	24
135	Antipsychotics and Mortality: Adjusting for Mortality Risk Scores to Address Confounding by Terminal Illness. Journal of the American Geriatrics Society, 2015, 63, 516-523.	2.6	18
136	Selective Serotonin Reuptake Inhibitor Use and Perioperative Bleeding and Mortality in Patients Undergoing Coronary Artery Bypass Grafting: A Cohort Study. Drug Safety, 2015, 38, 1075-1082.	3.2	10
137	Stakeholder assessment of comparative effectiveness research needs for Medicaid populations. Journal of Comparative Effectiveness Research, 2015, 4, 465-471.	1.4	3
138	Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Annals of the Rheumatic Diseases, 2015, 74, 1360-1367.	0.9	108
139	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Annals of the Rheumatic Diseases, 2015, 74, 1968-1975.	0.9	82
140	The Explanatory Role of Stroke as a Mediator of the Mortality Risk Difference Between Older Adults Who Initiate First- Versus Second-Generation Antipsychotic Drugs. American Journal of Epidemiology, 2014, 180, 847-852.	3.4	17
141	Ensuring Patient Privacy in Data Sharing for Postapproval Research. New England Journal of Medicine, 2014, 371, 1644-1649.	27.0	19
142	Measuring frailty using claims data for pharmacoepidemiologic studies of mortality in older adults: evidence and recommendations. Pharmacoepidemiology and Drug Safety, 2014, 23, 891-901.	1.9	114
143	Instrumental variable applications using nursing home prescribing preferences in comparative effectiveness research. Pharmacoepidemiology and Drug Safety, 2014, 23, 830-838.	1.9	7
144	A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. Pharmacoepidemiology and Drug Safety, 2014, 23, 619-627.	1.9	21

#	ARTICLE	IF	CITATIONS
145	Learning from Big Health Care Data. New England Journal of Medicine, 2014, 370, 2161-2163.	27.0	264
146	Metrics for covariate balance in cohort studies of causal effects. Statistics in Medicine, 2014, 33, 1685-1699.	1.6	207
147	Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations. Diabetologia, 2014, 57, 2237-2250.	6.3	46
148	Patients' Preferences in Anticoagulant Therapy. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 912-919.	2.2	28
149	Near-Real-Time Monitoring of New Drugs: An Application Comparing Prasugrel Versus Clopidogrel. Drug Safety, 2014, 37, 151-161.	3.2	15
150	"First-Wave" Bias When Conducting Active Safety Monitoring of Newly Marketed Medications with Outcome-Indexed Self-Controlled Designs. American Journal of Epidemiology, 2014, 180, 636-644.	3.4	18
151	Scalable Collaborative Infrastructure for a Learning Healthcare System (SCILHS): Architecture. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 615-620.	4.4	76
152	Comparative mortality risks of antipsychotic medications in community-dwelling older adults. British Journal of Psychiatry, 2014, 205, 44-51.	2.8	70
153	Plasmode simulation for the evaluation of pharmacoepidemiologic methods in complex healthcare databases. Computational Statistics and Data Analysis, 2014, 72, 219-226.	1.2	85
154	Quantifying the Role of Adverse Events in the Mortality Difference between First and Second-Generation Antipsychotics in Older Adults: Systematic Review and Meta-Synthesis. PLoS ONE, 2014, 9, e105376.	2.5	35
155	Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems. Pharmacoepidemiology and Drug Safety, 2014, 23, 1223-1225.	1.9	4
156	High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications. European Journal of Clinical Pharmacology, 2013, 69, 549-557.	1.9	56
157	Clinical and Health Care Use Characteristics of Patients Newly Starting Allopurinol, Febuxostat, and Colchicine for the Treatment of Gout. Arthritis Care and Research, 2013, 65, 2008-2014.	3.4	24
158	Treatment Dynamics of Newly Marketed Drugs and Implications for Comparative Effectiveness Research. Value in Health, 2013, 16, 1054-1062.	0.3	28
159	Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporosis International, 2013, 24, 237-244.	3.1	56
160	The incident user design in comparative effectiveness research. Pharmacoepidemiology and Drug Safety, 2013, 22, 1-6.	1.9	181
161	Methods for Comparative Effectiveness Research/Patient-Centered Outcomes Research: From Efficacy to Effectiveness. Journal of Clinical Epidemiology, 2013, 66, S1-S4.	5.0	20
162	Improved prediction of medical expenditures and health care utilization using an updated chronic disease score and claims data. Journal of Clinical Epidemiology, 2013, 66, 1118-1127.	5.0	48

#	ARTICLE	IF	CITATIONS
163	Adjuvant vancomycin for antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 472-478.	0.8	13
164	Sequential Value-of-Information Assessment for Prospective Drug Safety Monitoring Using Claims Databases. Medical Decision Making, 2013, 33, 949-960.	2.4	4
165	Risk of Ischemic Cerebrovascular and Coronary Events in Adult Users of Anticonvulsant Medications in Routine Care Settings. Journal of the American Heart Association, 2013, 2, e000208.	3.7	21
166	Response Letter to Eltonsy and Colleagues. Journal of the American Geriatrics Society, 2013, 61, 848-849.	2.6	0
167	Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2013, 65, 1600-1607.	3.4	108
168	Comment on "Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership". Statistics in Medicine, 2013, 32, 1073-1074.	1.6	3
169	Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer. Pharmacoepidemiology and Drug Safety, 2013, 22, 1239-1244.	1.9	21
170	Comment: Generic Substitution of Antiepileptic Drugs: A Systematic Review of Prospective and Retrospective Studies. Annals of Pharmacotherapy, 2012, 46, 303-304.	1.9	1
171	Bias in Comparative Effectiveness Studies Due to Regional Variation in Medical Practice Intensity. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, e61-4.	2.2	1
172	Implications of M Bias in Epidemiologic Studies: A Simulation Study. American Journal of Epidemiology, 2012, 176, 938-948.	3.4	75
173	Variation in Antipsychotic Treatment Choice Across US Nursing Homes. Journal of Clinical Psychopharmacology, 2012, 32, 11-17.	1.4	34
174	Medicare Part D's Impact on Antipsychotic Drug Use and Costs Among Elderly Patients Without Prior Drug Insurance. Journal of Clinical Psychopharmacology, 2012, 32, 3-10.	1.4	6
175	Beneficiaries With Cardiovascular Disease and the Part D Coverage Gap. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 387-395.	2.2	18
176	Newly marketed medications present unique challenges for nonrandomized comparative effectiveness analyses. Journal of Comparative Effectiveness Research, 2012, 1, 109-111.	1.4	11
177	Comparative Effectiveness of Preventative Therapy for Venous Thromboembolism After Coronary Artery Bypass Graft Surgery. Circulation: Cardiovascular Interventions, 2012, 5, 590-596.	3.9	32
178	Active Safety Monitoring of Newly Marketed Medications in a Distributed Data Network: Application of a Semi-Automated Monitoring System. Clinical Pharmacology and Therapeutics, 2012, 92, 80-86.	4.7	41
179	Association Between the Part D Coverage Gap and Adverse Health Outcomes. Journal of the American Geriatrics Society, 2012, 60, 1408-1417.	2.6	6
180	The Impact of Reducing Cardiovascular Medication Copayments on Health Spending and Resource Utilization. Journal of the American College of Cardiology, 2012, 60, 1817-1824.	2.8	58

#	ARTICLE	IF	CITATIONS
181	Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Medical Research Methodology, 2012, 12, 180.	3.1	33
182	No differences in cancer screening rates in patients with rheumatoid arthritis compared to the general population. Arthritis and Rheumatism, 2012, 64, 3076-3082.	6.7	30
183	Early Steps in the Development of a Claims-Based Targeted Healthcare Safety Monitoring System and Application to Three Empirical Examples. Drug Safety, 2012, 35, 407-416.	3.2	12
184	Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 480-486.	2.2	128
185	Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiology and Drug Safety, 2012, 21, 697-709.	1.9	65
186	An Eventâ€Based Approach for Comparing the Performance of Methods for Prospective Medical Product Monitoring. Pharmacoepidemiology and Drug Safety, 2012, 21, 631-639.	1.9	10
187	Response to commentary by Marcus and Gibbons. Pharmacoepidemiology and Drug Safety, 2012, 21, 713-713.	1.9	0
188	Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: A population-based cohort study. Journal of Bone and Mineral Research, 2012, 27, 789-796.	2.8	61
189	Comparative Safety of Antipsychotic Medications in Nursing Home Residents. Journal of the American Geriatrics Society, 2012, 60, 420-429.	2.6	69
190	Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2012, 36, 239-247.	3.7	42
191	A combined comorbidity score predicted mortality in elderly patients better than existing scores. Journal of Clinical Epidemiology, 2011, 64, 749-759.	5.0	728
192	Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development. Clinical Pharmacology and Therapeutics, 2011, 90, 777-790.	4.7	157
193	Time Series Evaluation of an Intervention to Increase Statin Tablet Splitting by General Practitioners. Clinical Therapeutics, 2011, 33, 235-243.	2.5	3
194	The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiology and Drug Safety, 2011, 20, 551-559.	1.9	111
195	Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic â€matrix designâ€. Pharmacoepidemiology and Drug Safety, 2011, 20, 675-683.	1.9	21
196	Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004. Pharmacoepidemiology and Drug Safety, 2011, 20, 1088-1097.	1.9	7
197	Accuracy of identifying neutropenia diagnoses in outpatient claims data. Pharmacoepidemiology and Drug Safety, 2011, 20, 709-713.	1.9	8
198	Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. Journal of Bone and Mineral Research, 2011, 26, 993-1001.	2.8	79

#	ARTICLE	IF	CITATIONS
199	Association Between Disease-Modifying Antirheumatic Drugs and Diabetes Risk in Patients With Rheumatoid Arthritis and Psoriasis. JAMA - Journal of the American Medical Association, 2011, 305, 2525.	7.4	332
200	Effects of Adjusting for Instrumental Variables on Bias and Precision of Effect Estimates. American Journal of Epidemiology, 2011, 174, 1213-1222.	3.4	205
201	Covariate Selection in High-Dimensional Propensity Score Analyses of Treatment Effects in Small Samples. American Journal of Epidemiology, 2011, 173, 1404-1413.	3.4	149
202	Comparison of Different Approaches to Confounding Adjustment in a Study on the Association of Antipsychotic Medication With Mortality in Older Nursing Home Patients. American Journal of Epidemiology, 2011, 174, 1089-1099.	3.4	26
203	The Effect of Altitude Change on Anemia Treatment Response in Hemodialysis Patients. American Journal of Epidemiology, 2011, 173, 768-777.	3.4	13
204	Availability of Comparative Efficacy Data at the Time of Drug Approval in the United States. JAMA - Journal of the American Medical Association, 2011, 305, 1786.	7.4	62
205	Changes in Drug Utilization during a Gap in Insurance Coverage: An Examination of the Medicare Part D Coverage Gap. PLoS Medicine, 2011, 8, e1001075.	8.4	36
206	Full Coverage for Preventive Medications after Myocardial Infarction. New England Journal of Medicine, 2011, 365, 2088-2097.	27.0	622
207	Variation in the Risk of Suicide Attempts and Completed Suicides by Antidepressant Agent in Adults. Archives of General Psychiatry, 2010, 67, 497.	12.3	65
208	Confounding Control in Healthcare Database Research. Medical Care, 2010, 48, S114-S120.	2.4	291
209	Privacy-Maintaining Propensity Score-Based Pooling of Multiple Databases Applied to a Study of Biologics. Medical Care, 2010, 48, S83-S89.	2.4	30
210	Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. Pharmacoepidemiology and Drug Safety, 2010, 19, 848-857.	1.9	43
211	Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiology and Drug Safety, 2010, 19, 537-554.	1.9	288
212	Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially insured population. Pharmacoepidemiology and Drug Safety, 2010, 19, 596-603.	1.9	156
213	A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiology and Drug Safety, 2010, 19, 858-868.	1.9	223
214	Identification of hospitalizations for intentional self-harm when E-codes are incompletely recorded. Pharmacoepidemiology and Drug Safety, 2010, 19, 1263-1275.	1.9	61
215	Medicare Beneficiaries' Knowledge of and Choices Regarding Part D, 2005 to the Present. Journal of the American Geriatrics Society, 2010, 58, 950-966.	2.6	31
216	Changes in Drug Use and Out-of-Pocket Costs Associated with Medicare Part D Implementation: A Systematic Review. Journal of the American Geriatrics Society, 2010, 58, 1764-1779.	2.6	48

#	ARTICLE	IF	CITATIONS
217	Refilling and Switching of Antiepileptic Drugs and Seizure-Related Events. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 347-353.	4.7	65
218	Anticonvulsant Medications and the Risk of Suicide, Attempted Suicide, or Violent Death. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1401.	7.4	204
219	Comparative Safety of Antidepressant Agents for Children and Adolescents Regarding Suicidal Acts. <i>Pediatrics</i> , 2010, 125, 876-888.	2.1	105
220	The Epidemiology of Prescriptions Abandoned at the Pharmacy. <i>Annals of Internal Medicine</i> , 2010, 153, 633.	3.9	98
221	Comparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 857.	7.4	99
222	Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2010, 31, 561-572.	2.2	56
223	Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2114-2117.	0.9	184
224	Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants. <i>Journal of Mental Health Policy and Economics</i> , 2010, 13, 37-44.	0.6	7
225	GRACE principles: recognizing high-quality observational studies of comparative effectiveness. <i>American Journal of Managed Care</i> , 2010, 16, 467-71.	1.1	103
226	Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin. <i>PLoS ONE</i> , 2009, 4, e6080.	2.5	20
227	Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome. <i>Circulation</i> , 2009, 120, 2322-2329.	1.6	210
228	Topical Treatments with Pimecrolimus, Tacrolimus and Medium- to High-Potency Corticosteroids, and Risk of Lymphoma. <i>Dermatology</i> , 2009, 219, 7-21.	2.1	68
229	High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data. <i>Epidemiology</i> , 2009, 20, 512-522.	2.7	870
230	Managing Drug-Risk Information – What to Do with All Those New Numbers. <i>New England Journal of Medicine</i> , 2009, 361, 647-649.	27.0	40
231	Antipsychotic Agents and Sudden Cardiac Death – How Should We Manage the Risk?. <i>New England Journal of Medicine</i> , 2009, 360, 294-296.	27.0	57
232	Completeness of retail pharmacy claims data: Implications for pharmacoepidemiologic studies and pharmacy practice in elderly patients. <i>Clinical Therapeutics</i> , 2009, 31, 2048-2059.	2.5	25
233	Can Improved Prescription Medication Labeling Influence Adherence to Chronic Medications? An Evaluation of the Target Pharmacy Label. <i>Journal of General Internal Medicine</i> , 2009, 24, 570-578.	2.6	33
234	The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. <i>Osteoporosis International</i> , 2009, 20, 895-901.	3.1	70



#	ARTICLE	IF	CITATIONS
235	Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 259-268.	1.9	27
236	NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 1134-1142.	1.9	8
237	Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 253-264.	3.7	196
238	Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 1226-1232.	5.0	146
239	Instrumental variables II: instrumental variable application—in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 1233-1241.	5.0	108
240	Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. <i>American Heart Journal</i> , 2009, 157, 613-619.	2.7	7
241	Assessing Residual Confounding of the Association between Antipsychotic Medications and Risk of Death using Survey Data. <i>CNS Drugs</i> , 2009, 23, 171-180.	5.9	22
242	Health Advisories and Patterns of Patient Monitoring Among New Users of Antidepressant Medications. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 590-594.	1.4	0
243	Effects of Prescription Coinsurance and Income-Based Deductibles on Net Health Plan Spending for Older Users of Inhaled Medications. <i>Medical Care</i> , 2009, 47, 508-516.	2.4	12
244	Outcomes in the Era of Bare-Metal Stents vs the Era of Drug-Eluting Stents. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 33.	7.4	0
245	An Evaluation of the Relationship Between the Implementation of a Newly Designed Prescription Drug Label at Target Pharmacies and Health Outcomes. <i>Medical Care</i> , 2009, 47, 1031-1035.	2.4	18
246	What if the Federal Government Negotiated Pharmaceutical Prices for Seniors? An Estimate of National Savings. <i>Journal of General Internal Medicine</i> , 2008, 23, 1435-1440.	2.6	22
247	Evaluating uses of data mining techniques in propensity score estimation: a simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 546-555.	1.9	195
248	The risk of infection associated with tumor necrosis factor $\alpha$ antagonists: Making sense of epidemiologic evidence. <i>Arthritis and Rheumatism</i> , 2008, 58, 919-928.	6.7	38
249	Potential Causes of Higher Mortality in Elderly Users of Conventional and Atypical Antipsychotic Medications. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 1644-1650.	2.6	90
250	The Effect of Transitioning to Medicare Part D Drug Coverage in Seniors Dually Eligible for Medicare and Medicaid. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 2304-2310.	2.6	31
251	Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death. <i>New England Journal of Medicine</i> , 2008, 358, 771-783.	27.0	331
252	Tumor necrosis factor- $\alpha$ antagonist use and heart failure in elderly patients with rheumatoid arthritis. <i>American Heart Journal</i> , 2008, 156, 336-341.	2.7	98

#	ARTICLE	IF	CITATIONS
253	Rationale and design of the Post-MI FREEE trial: A randomized evaluation of first-dollar drug coverage for postâ€œmyocardial infarction secondary preventive therapies. American Heart Journal, 2008, 156, 31-36.	2.7	41
254	Impact analysis of the discontinuation of reimbursement: the case of oral contraceptives. Contraception, 2008, 78, 399-404.	1.5	8
255	Instrumental Variable Analysis for Estimation of Treatment Effects With Dichotomous Outcomes. American Journal of Epidemiology, 2008, 169, 273-284.	3.4	132
256	The Effect of Altitude on Dosing and Response to Erythropoietin in ESRD. Journal of the American Society of Nephrology: JASN, 2008, 19, 1389-1395.	6.1	62
257	The Impact of Cost Sharing on Antidepressant Use Among Older Adults in British Columbia. Psychiatric Services, 2008, 59, 377-383.	2.0	19
258	Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly. Circulation, 2007, 115, 27-33.	1.6	145
259	Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Cmaj, 2007, 176, 627-632.	2.0	305
260	Sturmer et al. Respond to "Propensity Score Methods in Epidemiology". American Journal of Epidemiology, 2007, 165, 1122-1123.	3.4	14
261	Performance of Propensity Score Calibration—A Simulation Study. American Journal of Epidemiology, 2007, 165, 1110-1118.	3.4	101
262	Adherence to Statin Therapy Under Drug Cost Sharing in Patients With and Without Acute Myocardial Infarction. Circulation, 2007, 115, 2128-2135.	1.6	112
263	Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial Results. Medical Care, 2007, 45, S131-S142.	2.4	228
264	Ventricular Arrhythmias and Cerebrovascular Events in the Elderly Using Conventional and Atypical Antipsychotic Medications. Journal of Clinical Psychopharmacology, 2007, 27, 707-710.	1.4	40
265	Adjustments for Unmeasured Confounders in Pharmacoepidemiologic Database Studies Using External Information. Medical Care, 2007, 45, S158-S165.	2.4	68
266	Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal, 2007, 154, 260-266.	2.7	497
267	Reference drug programs: Effectiveness and policy implications. Health Policy, 2007, 81, 17-28.	3.0	35
268	Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. Journal of Clinical Epidemiology, 2007, 60, 397-409.	5.0	149
269	Understanding secondary databases: a commentary on â€œSources of bias for health state characteristics in secondary databasesâ€•. Journal of Clinical Epidemiology, 2007, 60, 648-650.	5.0	23
270	Antiâ€œtumor necrosis factor Î± therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 1754-1764.	6.7	270

#	ARTICLE	IF	CITATIONS
271	Developments in Post-marketing Comparative Effectiveness Research. Clinical Pharmacology and Therapeutics, 2007, 82, 143-156.	4.7	172
272	Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes and Control, 2007, 18, 561-569.	1.8	119
273	Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction. American Journal of Managed Care, 2007, 13, 445-52.	1.1	23
274	Initiation of Acetylcholinesterase Inhibitors and Complications of Chronic Airways Disorders in Elderly Patients. Drug Safety, 2006, 29, 1077-1085.	3.2	12
275	Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clinical Therapeutics, 2006, 28, 964-978.	2.5	52
276	Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. Journal of Clinical Epidemiology, 2006, 59, 18-25.	5.0	34
277	Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. Journal of Clinical Epidemiology, 2006, 59, 819-828.	5.0	115
278	Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiology and Drug Safety, 2006, 15, 291-303.	1.9	585
279	Methods in pharmacoepidemiology: time-varying drug effects revisited. Pharmacoepidemiology and Drug Safety, 2006, 15, 93-94.	1.9	3
280	Angiotensin inhibition after myocardial infarction: Does drug class matter?. Journal of General Internal Medicine, 2006, 21, 1242-1247.	2.6	9
281	A therapeutic substitution policy for proton pump inhibitors: Clinical and economic consequences. Clinical Pharmacology and Therapeutics, 2006, 79, 379-388.	4.7	44
282	Psychotropic medication use for behavioral symptoms of dementia. Current Neurology and Neuroscience Reports, 2006, 6, 490-495.	4.2	12
283	Tumor necrosis factor $\alpha$ antagonist use and cancer in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 2757-2764.	6.7	228
284	Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: An instrumental variable analysis. Arthritis and Rheumatism, 2006, 54, 3390-3398.	6.7	83
285	Patterns of cardiovascular risk in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2006, 65, 1608-1612.	0.9	341
286	Variable Selection for Propensity Score Models. American Journal of Epidemiology, 2006, 163, 1149-1156.	3.4	1,618
287	Assessing Health State Utilities in Elderly Patients at Cardiovascular Risk. Medical Decision Making, 2006, 26, 247-254.	2.4	13
288	Pharmacogenetic Testing in the Clinical Management of Schizophrenia. Journal of Clinical Psychopharmacology, 2005, 25, 427-434.	1.4	49

#	ARTICLE	IF	CITATIONS
289	Adjusting for Unmeasured Confounders in Pharmacoepidemiologic Claims Data Using External Information. <i>Epidemiology</i> , 2005, 16, 17-24.	2.7	101
290	Suboptimal Antidepressant Use in the Elderly. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 118-126.	1.4	54
291	Claims Data Studies of Sedative-Hypnotics and Hip Fractures in Older People: Exploring Residual Confounding Using Survey Information. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 948-954.	2.6	46
292	Identification of Individuals With CKD From Medicare Claims Data: A Validation Study. <i>American Journal of Kidney Diseases</i> , 2005, 46, 225-232.	1.9	198
293	Underuse of ACE Inhibitors and Angiotensin II Receptor Blockers in Elderly Patients With Diabetes. <i>American Journal of Kidney Diseases</i> , 2005, 46, 1080-1087.	1.9	72
294	Methods in pharmacoepidemiology: an invited series. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 453-454.	1.9	2
295	Adjusting Effect Estimates for Unmeasured Confounding with Validation Data using Propensity Score Calibration. <i>American Journal of Epidemiology</i> , 2005, 162, 279-289.	3.4	185
296	Analytic Strategies to Adjust Confounding using Exposure Propensity Scores and Disease Risk Scores: Nonsteroidal Antiinflammatory Drugs and Short-term Mortality in the Elderly. <i>American Journal of Epidemiology</i> , 2005, 161, 891-898.	3.4	155
297	Sudden Uncontrollable Somnolence and Medication Use in Parkinson Disease. <i>Archives of Neurology</i> , 2005, 62, 1242.	4.5	77
298	Effects of Noncardiovascular Comorbidities on Antihypertensive Use in Elderly Hypertensives. <i>Hypertension</i> , 2005, 46, 273-279.	2.7	75
299	A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. <i>Journal of Clinical Epidemiology</i> , 2005, 58, 98-102.	5.0	62
300	A review of uses of health care utilization databases for epidemiologic research on therapeutics. <i>Journal of Clinical Epidemiology</i> , 2005, 58, 323-337.	5.0	1,041
301	Underuse of Controller Medications Among Children With Persistent Asthma in the Ohio Medicaid Population: Evolving Differences With New Medications. <i>Academic Pediatrics</i> , 2005, 5, 83-89.	1.7	28
302	Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications. <i>New England Journal of Medicine</i> , 2005, 353, 2335-2341.	27.0	871
303	Performance of a rheumatoid arthritis records-based index of severity. <i>Journal of Rheumatology</i> , 2005, 32, 1679-87.	2.0	18
304	Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults. <i>Circulation</i> , 2004, 109, 2068-2073.	1.6	493
305	Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. <i>BMJ: British Medical Journal</i> , 2004, 328, 560.	2.3	58
306	Relationship Between COX-2 Specific Inhibitors and Hypertension. <i>Hypertension</i> , 2004, 44, 140-145.	2.7	148

#	ARTICLE	IF	CITATIONS
307	Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 Inhibitors. New England Journal of Medicine, 2004, 351, 2187-2194.	27.0	116
308	Consistency of performance ranking of comorbidity adjustment scores in canadian and U.S. utilization data. Journal of General Internal Medicine, 2004, 19, 444-450.	2.6	74
309	Therapeutic delay and reduced functional status six months after thrombolysis for acute myocardial infarction. American Journal of Cardiology, 2004, 94, 415-420.	1.6	17
310	Exposure misclassification as a result of free sample drug utilization in automated claims databases and its effect on a pharmacoepidemiology study of selective COX-2 inhibitors. Pharmacoepidemiology and Drug Safety, 2004, 13, 695-702.	1.9	18
311	Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. American Heart Journal, 2004, 148, 99-104.	2.7	489
312	Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. Annals of Epidemiology, 2004, 14, 296-303.	1.9	34
313	Association Between SSRI Use and Hip Fractures and the Effect of Residual Confounding Bias in Claims Database Studies. Journal of Clinical Psychopharmacology, 2004, 24, 632-638.	1.4	77
314	Net Health Plan Savings From Reference Pricing for Angiotensin-Converting Enzyme Inhibitors in Elderly British Columbia Residents. Medical Care, 2004, 42, 653-660.	2.4	44
315	Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clinical Pharmacology and Therapeutics, 2003, 74, 388-400.	4.7	55
316	Improved Comorbidity Adjustment for Predicting Mortality in Medicare Populations. Health Services Research, 2003, 38, 1103-1120.	2.0	273
317	Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?. American Journal of Medicine, 2003, 115, 715-720.	1.5	78
318	Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia. Clinical Therapeutics, 2003, 25, 273-284.	2.5	8
319	Costs of Measuring Outcomes of Acute Hospital Care in a Longitudinal Outcomes Measurement System. American Journal of Medical Quality, 2003, 18, 3-9.	0.5	2
320	Metric properties of the appropriateness evaluation protocol and predictors of inappropriate hospital use in Germany: an approach using longitudinal patient data. International Journal for Quality in Health Care, 2002, 14, 483-492.	1.8	26
321	Outcomes of Reference Pricing for Angiotensin-Converting Enzyme Inhibitors. New England Journal of Medicine, 2002, 346, 822-829.	27.0	164
322	Clozapine Use and Risk of Diabetes Mellitus. Journal of Clinical Psychopharmacology, 2002, 22, 236-243.	1.4	72
323	On the Evaluation of Drug Benefits Policy Changes with Longitudinal Claims Data. Disease Management and Health Outcomes, 2002, 10, 763-769.	0.4	2
324	Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance. Journal of Clinical Epidemiology, 2002, 55, 833-841.	5.0	36

#	ARTICLE	IF	CITATIONS
325	Measuring the cost-effectiveness of lipid-lowering drugs in the elderly:. Contemporary Clinical Trials, 2002, 23, 757-773.	1.9	8
326	Prescription Duration After Drug Copay Changes in Older People: Methodological Aspects. Journal of the American Geriatrics Society, 2002, 50, 521-525.	2.6	28
327	Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. European Journal of Clinical Pharmacology, 2002, 58, 285-291.	1.9	236
328	Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. Cmaj, 2002, 166, 737-45.	2.0	36
329	Pharmaceutical cost containment with reference-based pricing: time for refinements. Cmaj, 2002, 167, 1250-1.	2.0	5
330	On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective. Health Policy, 2001, 55, 97-109.	3.0	32
331	First results from an intensified monitoring system to estimate drug related hospital admissions. British Journal of Clinical Pharmacology, 2001, 52, 196-200.	2.4	28
332	A Case-Control Study of the Effect of Infant Feeding on Celiac Disease. Annals of Nutrition and Metabolism, 2001, 45, 135-142.	1.9	69
333	Performance of Comorbidity Scores to Control for Confounding in Epidemiologic Studies using Claims Data. American Journal of Epidemiology, 2001, 154, 854-864.	3.4	646
334	SENSITIVITY ANALYSIS OF THE DIAGNOSTIC VALUE OF ENDOSCOPES IN CROSS-SECTIONAL STUDIES IN THE ABSENCE OF A GOLD STANDARD. International Journal of Technology Assessment in Health Care, 2000, 16, 834-841.	0.5	7
335	Anorexigens and Pulmonary Hypertension in the United States. Chest, 2000, 117, 870-874.	0.8	183
336	Use of comorbidity scores for control of confounding in studies using administrative databases. International Journal of Epidemiology, 2000, 29, 891-898.	1.9	359
337	What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?. Health Policy, 1998, 44, 253-260.	3.0	40
338	Internet Surveys by Direct Mailing. Social Science Computer Review, 1997, 15, 242-255.	4.2	72
339	Measurement Error Correction for Logistic Regression Models with an "Alloyed Gold Standard". American Journal of Epidemiology, 1997, 145, 184-196.	3.4	127